← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	1,088	+60	+6%	$23.4B
2	2 Charles River Laboratories CRL $14.4B	407	+41	+11%	$5.18B
3	3 Sarepta Therapeutics SRPT $1.78B	336	-9	-3%	$7.5B
4	4 DELISTED CATALENT, INC. CTLT	267	-10	-4%	$4.54B
5	5 DELISTED bluebird bio BLUE	251	-37	-13%	$6.06B
6	6 DELISTED SANGAMO THERAPEUTICS INC SGMO	197	-20	-9%	$735M
7	7 Regenxbio RGNX $454M	183	-20	-10%	$1.26B
8	8 Precigen PGEN $2.64B	166	-4	-2%	$773M
9	9 Ultragenyx Pharmaceutical RARE $1.47B	165	-12	-7%	$2.2B
10	10 PTC Therapeutics PTCT $4.98B	164	-16	-9%	$1.67B
11	11 CRISPR Therapeutics CRSP $4.86B	155	-24	-13%	$631M
12	12 Vericel Corp VCEL $2.06B	150	+18	+14%	$635M
13	13 Intellia Therapeutics NTLA $1.6B	141	-16	-10%	$430M
14	14 Fate Therapeutics FATE $232M	122	+6	+5%	$762M
15	15 Atara Biotherapeutics ATRA $96M	121	+6	+5%	$1.68B
16	16 Voyager Therapeutics VYGR $124M	116	-3	-3%	$262M
17	ATHX 17 DELISTED Athersys, Inc. Common Stock ATHX	106	+7	+7%	$41.8M
18	18 Lineage Cell Therapeutics LCTX $232M	105	-1	-0.9%	$52.1M
19	19 Abeona Therapeutics ABEO $249M	99	-5	-5%	$232M
20	20 uniQure QURE $1.45B	94	-5	-5%	$656M
21	BLCM 21 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	92	-8	-8%	$68.7M
22	22 Rocket Pharmaceuticals RCKT $243M	87	+3	+4%	$622M
23	23 DELISTED Adverum Biotechnologies ADVM	86	-15	-15%	$121M
24	24 Lakefront Biotherapeutics American Depositary Shares LKFT $1.93B	85	-7	-8%	$746M
25	ADAP 25 DELISTED Adaptimmune Therapeutics ADAP	80	-13	-14%	$397M